Get Connected:

 

Latest News

GOP Senators Reveal Affordable Care Act Replacement Plan
The Better Care Reconciliation Act of 2017 was introduced Thursday.
Trend-in-trend model may predict safety concerns of new drugs.
A look at the top stories in pharmacy last week.
Review suggests that low doses of multiple blood pressure drugs may be more effective than a standard dose of only 1 medication. 
Dabrafenib and trametinib approved for patients with metastatic non-small cell lung cancer with BRAF V600E mutation.
Novel vaccine improves overall survival in non-small cell lung cancer.
Top news of the day from across the healthcare landscape.
An experimental leukemia drug may increase muscle strength in patients with Duchenne muscular dystrophy.
View More >

From the Journals

The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.
Given the need to provide patients with access to effective medications, it is likely that we will see more value-based contracts in the future; however, some key operational, communications, and regulatory barriers will need to be addressed first.
When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.    
The pharmacy benefit has begun to attract greater attention due to the increase in medications that are available and their cost. It is time we refocus on the needs of the patient and push ourselves and the benefit managers to evolve into a single integrated management and distribution model.
Among a population of adult patients with type 2 diabetes, adherence to oral hypoglycemic medications is independently associated with poor glycemic control, even after adjusting for patient-level covariates.

Adherence and access to higher-value care can make a big difference in reducing costs for patients and our healthcare system; however, the financial burden of high-deductible health plans and out-of-pocket costs must also be considered.

Patients with multiple chronic conditions are less likely to use generic drugs, even when facing lower co-payments.

Upcoming Partner Events